Filter Results

Clinical Studies

Open

Contact Us for the Latest Status

Closed for Enrollment

  • A Biobank for Pancreatic Diseases Rochester, Minn.

    To develop a resource (bank) of biospecimens and data collected from individuals with pancreatic diseases to facilitate discovery and development of novel biomarkers of risk and early detection, severity prediction, etiology and response to therapy.

     
  • Automating Colonoscopy Follow-up to Facilitate Appropriate Colonoscopy Surveillance Rochester, Minn.

    The primary goals of this project will be to standardize and enhance recommendations for colonoscopy surveillance intervals across the divisions of GIH and CRS and throughout the clinic practice
  • CPN1741 T-Cell Receptor Repertoire (TCR) Repertoire Pre- and Post-MUC1 Vaccine Rochester, Minn. Can T cell receptor repertoires serve as a biomarker of T cell response to a MUC1 vaccine?
  • Mayo Center for Cell Signaling Biobank (C-SiG Biobank) Rochester, Minn.

    The purpose of this study is to facilitate discovery and development of novel biomarkers of risk and early detection, etiologic factors relating to liver disease, and novel targeted therapeutic and chemopreventive strategies for liver disease such as PSC, PBC, PLD, NAFLD, NASH, ASH, HCC, donors (non-diseased and diseased) for liver transplant or non-liver diseased subjects scheduled for surgery will serve as controls.
  • Mayo Clinic Cancer Genomics Service Line Biorepository Rochester, Minn., Eau Claire, Wis., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    The goal of the study is to create a database of clinical information and a repository of biological specimens for genetic, molecular and microbiological research to better understand hereditary cancer and help develop new therapies and preventive strategies.
  • Prospective Study to Evaluate the Association of Pre-treatment Neutrophil to Lymphocyte ratio with Intestinal Permeability in Stage 3 Colon Cancer Patients Receiving Chemotherapy Rochester, Minn.

    To study intestinal permeability in participants with stage 3 colon cancer before and during chemotherapy and compare with controls with normal colon, chronic ulcerative colitis (CUC) and carcinoid syndrome

    To study the correlation between intestinal permeability and symptoms severity during 5-FU chemotherapy

    To study the correlation between intestinal permeability and neutrophils to lymphocytes ratio (NLR) before and during chemotherapy

    To analyze the changes in expression levels of genes encoding intercellular junction proteins in all groups

    To determine if diarrhea in participants with carcinoid syndrome is associated with increasedintestinal permeability
  • Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas Rochester, Minn. This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer overtime. Vaccines made from peptides may help the body build an effective immune response to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence of adenomatous polyps and may prevent the development of colorectal cancer.
  • The Circulating Cell-free Genome Atlas Study (CCGA) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

    GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.
.